These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 34771459)

  • 21. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
    Liu TH; Shen YC; Cheng AL
    J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
    Rallis KS; Makrakis D; Ziogas IA; Tsoulfas G
    World J Clin Oncol; 2022 Jun; 13(6):448-472. PubMed ID: 35949435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
    Ozer M; George A; Goksu SY; George TJ; Sahin I
    Front Oncol; 2021; 11():801379. PubMed ID: 34956912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitors in the Treatment of HCC.
    Donisi C; Puzzoni M; Ziranu P; Lai E; Mariani S; Saba G; Impera V; Dubois M; Persano M; Migliari M; Pretta A; Liscia N; Astara G; Scartozzi M
    Front Oncol; 2020; 10():601240. PubMed ID: 33585218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic treatment for unresectable hepatocellular carcinoma.
    Leowattana W; Leowattana T; Leowattana P
    World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Griffiths CD; Zhang B; Tywonek K; Meyers BM; Serrano PE
    JAMA Netw Open; 2022 Jul; 5(7):e2222721. PubMed ID: 35849393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.
    Lee YR
    J Liver Cancer; 2023 Sep; 23(2):316-329. PubMed ID: 37743048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials.
    Fulgenzi CAM; Scheiner B; Korolewicz J; Stikas CV; Gennari A; Vincenzi B; Openshaw MR; Silletta M; Pinter M; Cortellini A; Scotti L; D'Alessio A; Pinato DJ
    JHEP Rep; 2023 May; 5(5):100702. PubMed ID: 37025943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
    Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.
    Lee SW; Yang SS; Lien HC; Peng YC; Tung CF; Lee TY
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.
    Sharma R; Pillai A; Marron TU; Fessas P; Saeed A; Jun T; Dharmapuri S; Szafron D; Naqash AR; Gampa A; Wang Y; Khan U; Muzaffar M; Lee CJ; Lee PC; Bulumulle A; Paul S; Bettinger D; Hildebrand H; Yehia M; Pressiani T; Kaseb A; Huang YH; Ang C; Kudo M; Nishida N; Personeni N; Rimassa L; Pinato DJ
    Hepatol Commun; 2022 Jul; 6(7):1776-1785. PubMed ID: 35481940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy.
    Li SQ; Yang Y; Ye LS
    World J Gastroenterol; 2022 Nov; 28(42):6034-6044. PubMed ID: 36405383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TKIs in combination with immunotherapy for hepatocellular carcinoma.
    Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A
    Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
    Pinto E; Meneghel P; Farinati F; Russo FP; Pelizzaro F; Gambato M
    Dig Liver Dis; 2024 Apr; 56(4):579-588. PubMed ID: 37758610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
    Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure.
    Li X; Ding X; Li W; Chen J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1395-1403. PubMed ID: 36441192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
    Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
    Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.